Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.35 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.34 |
| ▸ | NAAA | Q02083 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10303327 | 0.89 | NAAA (0.39) | PDE4DPDE4APDE4BPDE4CNAAA | |
| SCHEMBL13654077 | 0.89 | PDE4D (0.37) | PDE4DPDE4APDE4BPDE4CNAAA | |
| SCHEMBL12823044 | 0.86 | PDE4A (0.30) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL12823491 | 0.86 | PDE4A (0.30) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL10303356 | 0.85 | PDE4A (0.37) | PDE4DPDE4APDE4BPDE4CGRIN2B | |
| SCHEMBL12823180 | 0.85 | ESR1 (0.33) | PDE4DPDE4APDE4BPDE4CGRIN2B | |
| SCHEMBL12223987 | 0.84 | ADRA2A (0.32) | ADRB2 | |
| SCHEMBL10303351 | 0.84 | ADRA2A (0.32) | ADRB2 | |
| SCHEMBL10303078 | 0.83 | GRIN2B (0.34) | PDE4DPDE4APDE4BPDE4CGRIN2B | |
| SCHEMBL10303380 | 0.83 | PDE4D (0.35) | PDE4DPDE4APDE4BPDE4CNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | PDE4D 2892/4885PDE4A 3506/4885PDE4B 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.